Getting a new medicine from approval to an Irish patient's prescription has long been criticised as painfully slow. New figures from the Department of Health and the HSE tell a different story: hundreds of new medicines delivered in recent years, and fresh agreements now targeting far faster decisions still.
The scale of what's already been approved
The numbers add up fast. Between 2021 and 2025, an additional €158 million in funding for new drugs facilitated the introduction of 270 new medicines in Ireland, the Minister for Health told the Dáil in a written answer in July 2026. Of the medicines approved under that funding since 2021, 110 were for cancer and 75 for rare diseases.
Budget 2026 went further, allocating €217 million in additional funding for medicines overall, including €30 million ring-fenced specifically for new medicines. By the end of March 2026, that had already delivered access to 13 new medicines, including 6 for cancer and 3 for rare diseases, according to the Minister's answer to a Dáil question in April 2026.
By June 2026, that number had risen to 30 new medicines funded under the 2026 allocation, including 7 for rare diseases, according to a further written answer from the Minister for Health in September 2026.
That same September answer confirmed the HSE's drugs budget for all medicines, including cancer drugs, stands at around €4 billion a year, with €30 million of that ring-fenced specifically for rare disease treatments - a figure Opposition TDs including Michael Cahill have repeatedly pressed to be raised to €200 million a year for patients such as those with Friedreich's ataxia awaiting the drug Skyclarys.
Why does the first-year figure never tell the whole story? Because the Department has continued to stress that the year-one cost of a new medicine is only ever a fraction of what it costs once fully rolled out to every eligible patient, which is why the HSE assesses each drug's five-year budget impact before making a reimbursement decision, rather than judging it on its first-year price alone.
New framework agreements: the 180-day target
The bigger structural change came in March 2026, when the Minister for Health, Jennifer Carroll MacNeill, signed new Framework Agreements on the Supply and Pricing of Medicines with the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland (MFI), covering 2026 to 2029. The agreements followed agreements in principle reached in January 2026.
For patients, the centrepiece is a structured commitment to move towards a 180-day timeline for reimbursement decisions on new medicines, alongside measures to encourage off-patent drug launches and strengthen security of supply to reduce shortages, according to the Department of Health's announcement.
Carroll MacNeill said the agreements send 'a strong message to patients and innovators that Ireland is a positive environment' for new medicines, at what the Department called 'a time of unprecedented uncertainty in international pharmaceutical policy'.
Reached in partnership with the Department of Public Expenditure, Infrastructure, Public Service and Digitalisation and the HSE, the 2026-2029 agreements are also designed to encourage off-patent drug launches, so that cheaper generic and biosimilar versions reach the market sooner once patents expire, freeing up money in the medicines budget for newer treatments, according to the Department's January 2026 announcement.
Notably, both IPHA and Medicines for Ireland signed up to the same 180-day ambition - a rare point of agreement between originator drug companies and the generics and biosimilars industry, who don't always share the same priorities in pricing negotiations. The Department has also said the target will be phased in gradually rather than applying overnight to every application, with the HSE and industry agreeing interim milestones over 2026 and 2027 so the Corporate Pharmaceutical Unit and the National Centre for Pharmacoeconomics can adjust their staffing and processes to cope with the faster pace, rather than risking a backlog building up elsewhere in the pipeline.
How the process actually works
Behind the headlines sits a fairly technical process. Applications for pricing and reimbursement go through the HSE's Corporate Pharmaceutical Unit, which acts as the interface between the health service and pharmaceutical companies. A drug must first have a marketing authorisation from the Health Products Regulatory Authority or the European Commission before a company can even apply for reimbursement.
The HSE's Drugs Group, which considers these applications, publishes its minutes monthly - a level of transparency that has increased through 2025 and into 2026, with minutes now published close to real time from January through June 2026.
The Minister has also noted that under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE holds sole statutory responsibility for pricing and reimbursement decisions, and that it considers the five-year budget impact of each medicine, since the first-year cost of a new drug is typically only a fraction of what it costs once fully rolled out to all eligible patients.
One patient's route through the system
Numbers only mean so much until you see what they look like for one family. Parliamentary questions through 2026, including on the drug Skyclarys for Friedreich's ataxia, have repeatedly asked the Minister to speed up the HSE Drugs Group's consideration of specific medicines, reflecting how closely patients and their public representatives now track a process that used to be almost invisible outside the pharmaceutical industry. A separate 2026 case involving a drug for progressive pulmonary fibrosis saw TDs ask the Minister directly about the timeline for the National Centre for Pharmacoeconomics' assessment, and about support for patients paying privately while a reimbursement decision is pending.
That growing public scrutiny, alongside the new Framework Agreements, is part of why the Department has begun publishing more granular figures on how many medicines have been approved and when, rather than only citing overall budget totals.
Patient advocacy groups such as the Irish Platform for Patient Organisations, Science and Industry have welcomed the more detailed reporting, arguing that clearer, more frequent data on approval numbers makes it easier for individual patients and their GPs to know where a specific application stands, rather than having to rely on ad hoc parliamentary questions to find out.
Where the money and the pressure points are
None of this happens in a vacuum. Overall health funding for 2026 reached a record €27.4 billion, a €1.5 billion or 6.2% increase on 2025, the Department of Health announced in October 2025, part of what it described as a shift to a more performance-led model of investment across the country's six new Health Regions.
The Minister has also pointed out that Ireland is among the highest health spenders in the EU and has the third-highest rate of state coverage of pharmaceutical expenditure in Europe, according to OECD data cited in a July 2026 Dáil answer.
Still, campaigners keep pressing for faster access for rare disease patients specifically - Dáil questions in 2026 have called for the rare disease drugs budget to rise from €30 million to €200 million a year - a reminder that even as the system moves faster overall, demand for quicker rare-disease access remains a live and unresolved conversation.
The new Framework Agreements also address a less visible but important issue: continuity of supply. Both the IPHA and MFI agreements include dedicated clauses on security of supply, requiring companies to give advance notice of anticipated shortages and to hold buffer stock for certain categories of medicine, in a bid to reduce the disruption seen in Ireland and across Europe in recent years when manufacturing problems or export restrictions abroad left pharmacy shelves short of common drugs.
The agreements also set out a joint 'Programme of Change' for pricing and reimbursement, covering how the HSE and industry will work together over the 2026-2029 term to streamline the assessment pathway further, including clearer criteria for selecting best-value biosimilar and generic medicines once patents expire, according to the published IPHA and MFI agreement texts.
The Bottom Line
The direction of travel is unmistakable: 270 new medicines reimbursed since 2021, a further 30 added in the first half of 2026 alone, a record €217 million medicines budget for 2026, and a new multi-year pricing agreement with industry built around a 180-day target for reimbursement decisions. It's not instant, and rare disease campaigners are right to want it faster still - but the system Irish patients rely on to get new treatments is measurably quicker and better funded than it was even two years ago.
Health Pulse — Ireland's home for health and healthcare intelligence. Subscribe to the Pulse Network Briefing.